Numinus Clarifies Disclosures
Numinus Clarifies Disclosures
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, wishes to clarify two news releases disseminated on May 30, 2024, titled "Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder" ("Release 1") and "Numinus Wellness Charts Path To Profitability While Strengthening Community Ties" ("Release 2" and, together with Release 1, collectively, the "Releases").
不列顛哥倫比亞省溫哥華--(新聞資訊公司-2024年6月7日)-Numinus Wellness Inc.(TSX：NUMI)(OTCQX：NUMIF)，一家醫療保健公司，通過傳統的和創新的行爲健康治療，致力於安全、基於證據的致幻輔助療法，願意澄清2024年5月30日發佈的兩個新聞稿，題爲"Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder"("發佈1")和"Numinus Wellness Charts Path To Profitability While Strengthening Community Ties"("發佈2")，以及發佈1和發佈2一起被稱爲"發佈"。這些發佈是由一家公共關係公司無心泄露的，代表了公司以前發佈的信息。公司對任何可能引起的困惑表示歉意。Numinus"或"公司，一家精神醫療保健公司，致力於通過安全、基於證據的致幻輔助治療傳統和創新的行爲健康治療，希望澄清2024年5月30日發佈的兩個新聞稿，題爲"Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder"("發佈1")和"Numinus Wellness Charts Path To Profitability While Strengthening Community Ties"("發佈2")，以及發佈1和發佈2一起被稱爲"發佈"。發佈1Numinus Wellness發佈了兩份新聞稿："Numinus Wellness宣佈發行私人安全無擔保債務證券"（"發行1"）和"Numinus Wellness加強社區聯繫的盈利路徑"（"發行2"），兩者合起來是"發佈2Numinus Wellness發佈了兩份新聞稿："Numinus Wellness宣佈發行私人安全無擔保債務證券"（"發行1"）和"Numinus Wellness加強社區聯繫的盈利路徑"（"發行2"），兩者合起來是"發佈").
The Releases were inadvertently disseminated by a public relations firm contracted by the Company and represent information that was previously disseminated by the Company. The Company apologizes for any confusion.
這些發佈是由一家公共關係公司無心泄露的，代表了公司以前發佈的信息。公司對任何可能引起的困惑表示歉意。
Release 1
發佈1
The Company confirms that Cedar Clinical Research ("CCR"), has been engaged by Cybin Inc. ("Cybin") to provide clinical research services and that its Murray, Utah, location will be one of 15 U.S. research sites for Cybin's Phase 3 multinational clinical trial of CYB003. However, Dr. Paul Thielking is the Site Principal Investigator for the CCR site, and he is not the trial's Principal Investigator. Numinus has no direct or indirect ownership interest in CYB003. As such, results of any CYB003 research are the property of its sponsor, Cybin, and findings would be shared by Cybin if, as and when Cybin deems appropriate.
公司確認Cedar Clinical Research("CCR")已經爲Cybin Inc.("Cybin")提供臨床研究服務，並且它的猶他州默裏位置將成爲Cybin的CYB003多國臨床試驗的15個美國研究站之一。然而，Paul Thielking醫生是CCR站點的主要研究員，而不是試驗的主要研究員。Numinus對CYB003沒有直接或間接的所有權利。因此，CYB003研究的結果是其贊助商Cybin的財產，如果Cybin認爲適當，研究結果將由Cybin分享。CCRCybinCybin它將與另外14個美國研究機構一起成爲Cybin的CYB003全球臨床試驗的美國研究地點之一，爲提供臨床研究服務進行投資。但是，CCR網站的首席研究員是Paul Thielking博士，而不是該試驗的首席研究員。Numinus沒有CYB003的直接或間接所有權。因此，CYB003研究的任何結果都是其贊助商Cybin的財產，如果Cybin認爲合適，Cybin會分享研究結果。
Please refer to the Company's news release dated April 17, 2024, and titled "Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003" for details regarding the Company's role in CYB003 (the "CYB003 Release").
請參考公司2024年4月17日發佈的名爲"Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003"的新聞資訊，以獲取有關該公司在CYB003中的作用的詳細信息。這個新聞資訊被稱爲"CYB003發佈"。CYB003發佈").
Release 2
發佈2
The Company confirms that it plans to launch a Numinus Network community pilot, which will be made available to its current therapists and other practitioners, alumni of its training program, and former therapists and other practitioners, including those who join the Canadian Centre for Psychedelic Healing ("CCPH") when it is launched. In addition to training, the Numinus Network provides access to Numinus treatment protocols, promotional support, and access to Numinus' extensive network of experienced health care professionals. However, the planned community pilot program and Numinus Network do not provide access to medical infrastructure for the therapeutic administration of ketamine and other psychedelic drugs within Canada's regulatory framework, which may be through a program such as CCPH's co-op program. Further, there can be no assurance that a subscription-based model of the Numinus Network will be rolled out in Canada and/or the U.S.
公司確認將推出Numinus Network社區試點項目，該項目將面向其現有的治療師和其他從業者、其培訓計劃的畢業生以及前治療師和其他從業者，包括那些加入加拿大致幻療法中心("CCPH")的人員。CCPHNuminus Network在推出時將爲您提供培訓、Numinus治療協議的使用、促銷支持和使用經驗豐富的醫療保健專業人員的服務。不過，根據加拿大的監管框架，在社區試點計劃和Numinus Network中並不能訪問用於給予****和其他致幻藥物的診療基礎設施，可能需要通過CCPH的合作計劃。此外，在加拿大和/或美國推出基於訂閱的Numinus Network的模式也無法保證。
The Company further confirms that it and CCPH have agreed in principle to collaborate on the development of training content for the Numinus learning platform. However, the terms of this collaboration shall be mutually agreed in a subsequent agreement.
公司進一步確認，公司與CCPH原則上已經合作開發Numinus平台的培訓內容，不過具體條款將在隨後的協議中進行雙方協商確認。
Please refer to the Company's news release dated April 15, 2024, and titled "Numinus Wellness Provides Corporate Update" for further details (the "Update Release").
有關“Numinus Wellness提供企業更新”的詳細信息，請參閱於2024年4月15日發佈的公司新聞稿件（以下稱“更新發布”）。更新發布").
Important Information regarding the Releases
有關發佈的重要信息
The Releases included statements that are future oriented information concerning our plans, intentions, and expectations, which are not historical in nature. Such statements are subject to risks and uncertainties and there can be no assurance that those plans, intentions, and/or expectations will occur. Please refer to the CYB003 Release for disclosures concerning forward-looking statements in Release 1 and refer to the statement below under the heading "Forward-looking statements" as well as Update Release for disclosures concerning forward-looking statements in Release 2.
各發布中包含了關於我們計劃、意圖和期望的面向未來信息，這些信息不具有歷史性質。此類聲明存在風險和不確定性，不能確保計劃、意圖和/或期望一定能夠實現。請參閱關於發佈1中面向未來聲明的CYB003發佈以獲取相關披露，並參閱下面的“前瞻性聲明”條款以及更新發布以獲取有關發佈2中面向未來聲明的披露信息。
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research, clinic care and practitioner training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain, and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Numinus Wellness Inc.（TSX：NUMI）通過開發和提供創新的心理健康治療方法和安全的、基於證據的輔助致幻療法，幫助人們得以恢復健康。Numinus處於治療、而非精神健康症狀管理的前沿。在Numinus，我們致力於領導心理治療方式的轉型，重視患者的癒合，而非僅僅壓制症狀。我們正在引領心理健康療法的融入主流臨床實踐，爲建立一個更健康的社會奠定基礎。
Numinus Wellness Inc. (TSX：NUMI）致力於通過開發和提供創新的心理健康護理服務以及安全的、以證據爲基礎的致幻藥協助療法來幫助人們康復和獲得健康。Numinus醫療模型——包括致幻藥研究、診所護理和從業人員培訓——處於通過治療而不是管理抑鬱症、焦慮症、創傷後應激障礙、疼痛和物質成癮症狀的變革前沿。在Numinus，我們正在引領致幻藥協助療法融入主流臨床實踐，併爲建立更健康的社會奠定基礎。
Learn more at and follow us on LinkedIn, Facebook, Twitter, and Instagram.
了解更多信息請訪問，關注我們的LinkedIn、Facebook、Twitter和Instagram。
SOURCE Numinus Wellness Inc.
方正證券納米健康有限公司。
Forward-looking statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the successful launch and commercialization of the Numinus Network, uptake of the Numinus Network offering by practitioners, commercial viability of any or all of the Numinus Network members, availability or continued availability of the services to be delivered to Numinus Network members, client uptake of services from members of the Numinus Network; disclosures concerning forward-looking statements in the Releases; and other risks that are set forth in our annual information form dated November 29, 2023 and available on SEDAR at . Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
前瞻性聲明
本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明（包括與我們社會、環境和其他可持續性目標有關的聲明）的非歷史事實的前瞻性聲明，是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的，或者必須披露在我們向證券交易委員會（“SEC”）或其他監管機構的備案中。此外，歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設，在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設，並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
本新聞稿所含的有關預期未來事件的語句和其他信息構成前瞻性聲明。前瞻性聲明通常通過使用“尋求”、“預計”、“相信”、“計劃”、“估計”、“期望”和“打算”這類措辭以及“可能”、“將會”、“應當”、“可能會”或其他類似表達來識別。前瞻性聲明存在風險和不確定性因素，還有其他可能導致實際結果與前瞻性聲明所述的結果不同的因素。因此，不能確保Nuuminus Network的成功推出和商業化、從業者對Nuuminus Network方案的接受或任何或全部Numinus Network成員的商業可行性、向Numinus Network成員提供服務的可用性或持續可用性、客戶使用Numinus Network成員的服務的程度。此外請參閱於2023年11月29日發佈的年度信息表格以及SEDAR網站上公開披露的風險會影響前瞻性聲明事項。前瞻性聲明是基於管理層的估計和觀點在發佈時作出的。Nuuminus不承諾隨着情況變化或管理層的估計或觀點變化及時更新前瞻性聲明，除非適用法律要求。投資者不應過度依賴前瞻性聲明。前瞻性陳述是根據管理層的估計和意見於陳述發佈之日製作的。即使情況發生變化或者管理層的估計或者意見發生變化，Numinus也不承諾更新前瞻性陳述，除非適用法律要求。投資者不應過分依賴前瞻性陳述。
For more information:
欲了解更多信息：
Numinus
Investor Contact: Craig MacPhail invest@numinus.com
Numinus
投資者聯繫：Craig MacPhail invest@numinus.com
-30-
-30-
譯文內容由第三人軟體翻譯。